

# Psychiatric Services, PA

**Mason Robison**  
M.D. L.F.A.P.A.

493 Eastland; P.O. Box 47  
Twin Falls, ID 83303

**Barbara Robison**  
DSc, MSN, APRN, BC  
(Clinical Nurse Specialist)

Bus: 208-732-0995  
Fax: 208-732-0993

**Matthew Jolley**  
M.D.


July 28, 2010

To: Tami Eide, PharmD  
3232 Elder St.  
Boise, Idaho 83705

Dear Ms. Eide,

Please consider your continued approval of Risperdal Consta. We have found it very useful in our practice. It helps compliance, reduced hospitalizations, and costs.

Sincerely,

  
Mason Robison, MD  
L.F.A.P.A.



July 23, 2010

## Centers of Excellence

### Rheumatology Center

W. Patrick Knibbe, MD<sup>†</sup>  
James E. Loveless, MD<sup>†</sup>  
Michelle Hicks, FNP-C  
Janean Jenkins, PA-C  
Victoria Merrell, PA-C

### Hand & Wrist Center

Steven B. Care, MD<sup>\*0</sup>  
Louis E. Murdock, MD<sup>\*0</sup>  
Brandon Lane, PA-C

### Foot & Ankle Center

Steven E. Roser, MD<sup>\*</sup>  
Amber Carley, PA

### Joint Replacement Center

Dennis R. McGee, MD<sup>\*</sup>  
Colin E. Poole, MD<sup>\*</sup>  
Erik Heggland, MD<sup>\*</sup> *Shoulders*  
Nicole Femino-Pyle, PA-C  
Pamela Fields, NP-C

### Pediatric Orthopaedic Center

Kevin G. Shea, MD<sup>\*</sup>  
Buzz Showalter, MD<sup>\*</sup>  
Jason F. Robison, MD<sup>0</sup>  
Amy Waselchuk, PA-C

### Spine & Scoliosis Center

Howard A. King, MD<sup>\*</sup>  
Jason F. Robison, MD<sup>0</sup>  
Angie Coyne, PA-C

### Sports Medicine Center

Michael J. Curtin, MD<sup>\*</sup>  
Erik Heggland, MD<sup>\*</sup>  
Kevin G. Shea, MD<sup>\*</sup>  
Alex Homaechevarria, MD<sup>†</sup>  
Kurt Nilsson, MD, MS<sup>0</sup>  
Kati Johnson, PA-C

### Pharmacy and Therapeutics Committee

Attention: Tammy Eide, PharmD  
3232 Elder Street  
Boise, ID 83705

Dear Dr. Eide:

I am a consulting rheumatologist who does the majority of pediatric rheumatology in the state of Idaho and surrounding catchment area. I have been asked to provide input on the upcoming discussions by the P&T Committee for Medicaid on biologic therapy. Biologic therapy for rheumatoid arthritis and juvenile idiopathic arthritis has revolutionized the treatment of these diseases and provided disease modification that was previously not available as of the late 90s. Available agents for juvenile idiopathic arthritis include Enbrel 25-50 mg weekly, Humira 20-40 mg every other week, and Orencia in various doses IV monthly. It is essential that we have all of these agents available for us on the formulary. Response to any of these agents is not 100%, even though it is quite good with all agents, and it is quite necessary to have these therapeutically equivalent medications available for various patients.

Access to all available agents is essential in treating adult rheumatoid arthritis as well. There are now four available injection therapies for adult rheumatoid arthritis (Enbrel, Humira, Cimzia, and Simponi), as well as IV therapies (Remicade, Rituxan, Orencia, and Actemra). Again, it is essential that our patients have access to all available therapies, given the lack of 100% response to any of these medications. Different modes of action for these agents make it quite likely that an effective therapy can be found for each patient but only if we have access to all available therapies on a level basis.

I will welcome further discussion regarding this issue and appreciate your consideration of my opinion.

Respectfully submitted,

W. Patrick Knibbe, MD, FACP  
President, Association of Idaho Rheumatologists

cc: Peggy Rupp, MD; Fax: 208-322-0335  
cc: Achini Dingman, MD; Fax: 208-367-8099  
cc: Daryl MacCarter, MD; Fax: 208-887-9800  
cc: Mikael D. Lagwinski, MD; Fax: 208-887-9800  
cc: Kelly A. Timmons, MD, PhD; Fax: 208-463-3044  
cc: James E. Loveless, MD, FACP

WPK/dss

<sup>†</sup>ABOS, <sup>†</sup>ABFM, <sup>†</sup>FACP, <sup>0</sup>BE  
<sup>0</sup>CAQ Hand Surgery, ASSH